Fingerprint
Dive into the research topics of 'Phase I clinical trial combining imatinib mesylate and IL-2 HLA-DR+ NK cell levels correlate with disease outcome'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I clinical trial combining imatinib mesylate and IL-2 HLA-DR+ NK cell levels correlate with disease outcome
Nathalie Chaput, Caroline Flament, Clara Locher, Mélanie Desbois, Annie Rey, Sylvie Rusakiewicz, Vichnou Poirier-Colame, Patricia Pautier, Axel Le Cesne, Jean Charles Soria, Angelo Paci, Michelle Rosenzwajg, David Klatzmann, Alexander Eggermont, Caroline Robert, Laurence Zitvogel
Research output: Contribution to journal › Article › peer-review
24
Citations
(Scopus)